Cercar

08/03/2023 Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker
Martinez-Bosch, N, Vilarino, N, Alameda, F, Mojal, S, Arumi-Uria, M, Carrato, C, Aldecoa, I, Ribalta, T, Vidal, N, Bellosillo, B, Menendez, S, Del Barco, S, Gallego, O, Pineda, E, Lopez-Martos, R, Hernandez, A, Mesia, C, Esteve-Codina, A, de la Iglesia, N, Balana, C, Martinez-Garcia, M, Navarro, P. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker. Cells. 2023; 12(6)DOI:10.3390/cells12060843. PMID:36980184. IF:5.100(Q2/4D).
27/02/2023 Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
Chmielecki, J, Gray, JE, Cheng, Y, Ohe, Y, Imamura, F, Cho, BC, Lin, MC, Majem, M, Shah, R, Rukazenkov, Y, Todd, A, Markovets, A, Barrett, JC, Hartmaier, RJ, Ramalingam, SS. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 2023; 14(1)DOI:10.1038/s41467-023-35961-y. PMID:36849494. IF:14.700(Q1/1D).
14/02/2023 Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312] (Cancer Treatment Reviews (2022) 102, (S0305737221001602), (10.1016/j.ctrv.2021.102312))
Blay J.Y., Hindi N., Bollard J., Aguiar S., Jr., Angel M., Araya B., Badilla R., Bernabeu D., Campos F., Caro-Sánchez C.H.S., Carvajal B., Carvajal Montoya A., Casavilca-Zambrano S., Castro-Oliden V., Chacón M., Clara M., Collini P., Correa Genoroso R., Costa F.D., Cuellar M., dei Tos A.P., Dominguez Malagon H.R., Donati D., Dufresne A., Eriksson M., Farias-Loza M., Fernandez P., Frezza A.M., Frisoni T., Garcia-Ortega D.Y., Gelderblom H., Gouin F., Gómez-Mateo M.C., Gronchi A., Haro J., Huanca L., Jimenez N., Karanian M., Kasper B., Lopes David B.B., Lopez-Pousa A., Lutter G., Martinez-Said H., Martinez-Tlahuel J., Mello C.A., Morales Pérez J.M., Moura David S., Nascimento A.G., Ortiz-Cruz E.J., Palmerini E., Patel S., Pfluger Y., Provenzano S., Righi A., Rodriguez A., Salas R., Santos T.T.G., Scotlandi K., Soule T., Stacchiotti S., Valverde C., Waisberg F., Zamora Estrada E., Martin-Broto J.. Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312] (Cancer Treatment Reviews (2022) 102, (S0305737221001602), (10.1016/j.ctrv.2021.102312)). CANCER TREATMENT REVIEWS. 2023; 115DOI:10.1016/j.ctrv.2023.102523. PMID:36796283. IF:9.600(Q1/1D).
01/02/2023 Direct materials for restoring caries lesions Systematic review and meta-analysis-a report of the American Dental Association Council on Scientific Affairs
Pilcher, L, Pahlke, S, Urquhart, O, O'Brien, KK, Dhar, V, Fontana, M, Gonzalez-Cabezas, C, Keels, MA, Mascarenhas, AK, Nascimento, MM, Platt, JA, Sabino, GJ, Slayton, RL, Tinanoff, N, Young, DA, Zero, DT, Tampi, MP, Purnell, D, Salazar, J, Megremis, S, Bienek, D, Carrasco-Labra, A. Direct materials for restoring caries lesions Systematic review and meta-analysis-a report of the American Dental Association Council on Scientific Affairs. JOURNAL OF THE AMERICAN DENTAL ASSOCIATION. 2023; 154(2)DOI:10.1016/j.adaj.2022.09.012. PMID:36610925. IF:3.100(Q1/2D).
02/01/2023 Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma
Trilla-Fuertes L., Gámez-Pozo A., Prado-Vázquez G., López-Vacas R., Zapater-Moros A., López-Camacho E., Lumbreras-Herrera M.I., Soriano V., Garicano F., Lecumberri M.J., de la Borbolla, MR, Majem M., Pérez-Ruiz E., González-Cao M., Oramas J., Magdaleno A., Fra J., Martín-Carnicero A., Corral M., Puértolas T., Ramos R., Vara, JAF, Espinosa E.. Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(1)DOI:10.3390/ijms24010801. PMID:36614248. IF:4.900(Q1/3D).
01/01/2023 Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial
Peters S., Letovanec I., Mauer M., Dafni U., Ejedepang D., Biernat W., Bubendorf L., Warth A., Pokharel S., Reinmuth N., Tarruella, MM, Casas-Martin J., Tsourti Z., Marti N., Kammler R., Danson S., O'Brien M., Stahel R.A.. Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial. LUNG CANCER. 2023; 175DOI:10.1016/j.lungcan.2022.12.004. PMID:36535121. IF:4.500(Q1/2D).